TwinBeech Capital’s Myriad Genetics MYGN Stock Holding History

TwinBeech Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,136	Closed	-$69.8K	–	743
2025 Q2	$69.8K	Buy	+13,136	New	+$77.6K	﹤0.01%	601
2025 Q1	–	Sell	-40,975	Closed	-$562K	–	873
2024 Q4	$562K	Buy	+40,975	New	+$756K	0.01%	437
2021 Q4	–	Sell	-32,598	Closed	-$1.05M	–	727
2021 Q3	$1.05M	Buy	+32,598	New	+$1.08M	0.07%	319

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TwinBeech Capital's MYGN Position: Q3 2025 in Review

TwinBeech Capital sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 13,136 shares — an estimated $69.8K sold.

TwinBeech Capital first reported a position in MYGN in Q3 2021 and held it in 3 quarters. The position peaked at $1.05M in Q3 2021. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

TwinBeech Capital reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 13,136 Myriad Genetics shares in Q3 2025, an estimated $69.8K.
TwinBeech Capital first reported a position in Myriad Genetics in Q3 2021 and held it in 3 quarters.
TwinBeech Capital's Myriad Genetics position peaked at $1.05M in Q3 2021.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.